Can I Take Lion's Mane with Vyvanse?

How Vyvanse Works in the Body

Vyvanse (lisdexamfetamine dimesylate) is a prodrug approved by the FDA for attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 and older and for moderate-to-severe binge eating disorder in adults. The active molecule only becomes available after enzymatic hydrolysis in red blood cells converts lisdexamfetamine into d-amphetamine and L-lysine [1].

A Unique Metabolic Pathway

Unlike most CNS drugs, Vyvanse does not rely on cytochrome P450 (CYP450) enzymes for activation or clearance. This distinction matters because the majority of supplement-drug interactions happen at the CYP450 level. Because red blood cell hydrolysis is the rate-limiting step, substances that inhibit or induce liver enzymes (CYP3A4, CYP2D6, etc.) have minimal influence on lisdexamfetamine pharmacokinetics [1].

Downstream Neurotransmitter Effects

Once converted, d-amphetamine increases synaptic concentrations of dopamine and norepinephrine by promoting vesicular release and blocking reuptake via the dopamine transporter (DAT) and norepinephrine transporter (NET). Peak plasma concentration occurs roughly 3.5 hours after an oral dose, and the clinical effect window spans 10 to 14 hours in most adults [1]. That extended duration is relevant when considering supplement timing.

What Lion's Mane Does

Lion's mane (Hericium erinaceus) is an edible mushroom with a long history of use in East Asian traditional medicine. Modern research has focused on two compound families extracted from its fruiting body and mycelium: hericenones and erinacines. Both cross the blood-brain barrier in animal models and stimulate the synthesis of nerve growth factor (NGF) [2].

NGF and BDNF Stimulation

A 2023 study published in the Journal of Neurochemistry demonstrated that lion's mane active compounds promoted hippocampal neurite outgrowth through NGF-dependent pathways in mice, with increases in BDNF gene expression observed at oral doses equivalent to roughly 500 mg/kg [3]. This neurotrophic activity is the primary reason people with ADHD become interested in lion's mane: the hypothesis that boosting NGF and BDNF could support attention and cognitive flexibility on top of stimulant therapy.

Cognitive Effects in Humans

A double-blind, placebo-controlled trial by Mori et al. (2009, N=30) found that Japanese adults aged 50 to 80 with mild cognitive impairment who received 250 mg lion's mane tablets three times daily for 16 weeks scored significantly higher on the Revised Hasegawa Dementia Scale compared with placebo (P<0.05) [4]. Scores declined after a 4-week washout, suggesting the effect depends on continued supplementation. No serious adverse events were reported. A smaller pilot by Saitsu et al. (2019, N=49) found improvements in cognitive function scores in healthy adults over 12 weeks at 3.2 g/day of lion's mane extract [5].

These trials did not include participants taking stimulant medications, so direct extrapolation to a Vyvanse-plus-lion's-mane scenario is limited.

Is There a Direct Pharmacokinetic Interaction?

No. Based on current evidence, lion's mane does not meaningfully inhibit or induce the CYP450 enzymes most relevant to amphetamine metabolism (CYP2D6, CYP1A2). And as noted above, Vyvanse bypasses CYP450 entirely for its activation step [1].

Why CYP450 Status Matters Less Here

A 2020 in vitro screening by Kim et al. Examined Hericium erinaceus extracts against a panel of CYP isoforms and found weak inhibition of CYP1A2 at concentrations well above typical oral dosing ranges, with no significant activity against CYP2D6 or CYP3A4 [6]. Even if CYP2D6 inhibition were present, the rate-limiting step for Vyvanse is red blood cell hydrolysis, not hepatic metabolism. This makes a pharmacokinetic collision between the two substances unlikely.

No Transporter Competition Identified

Lion's mane compounds have not been shown to interact with DAT or NET, the transporters through which d-amphetamine exerts its primary effects. The neurotrophic mechanism (NGF/BDNF upregulation) operates through TrkA and TrkB receptor pathways, which are structurally and functionally distinct from monoamine reuptake [2][3].

The Pharmacodynamic Overlap Worth Watching

While the pharmacokinetic risk is low, there is a pharmacodynamic question. Both Vyvanse and lion's mane influence neuroplasticity and neurotransmitter tone, albeit through different mechanisms. The theoretical concern is additive or unpredictable modulation of neural signaling when both are on board.

Neurotrophic Signaling

D-amphetamine itself has been shown to increase BDNF expression acutely in animal models [7]. Lion's mane also increases BDNF [3]. Whether stacking two BDNF-elevating interventions produces a clinically meaningful change in humans remains unstudied. The biological plausibility is there, but the magnitude is unknown.

Mild Antiplatelet Activity

Hericenones isolated from lion's mane fruiting bodies inhibited collagen-induced platelet aggregation in vitro, as reported by Mori et al. (2010) [8]. Vyvanse can raise heart rate and blood pressure, which may theoretically increase bleeding risk in a person whose platelet function is mildly suppressed. This is a low-probability scenario at typical supplement doses (500 to 3,000 mg/day of standardized extract), but it becomes relevant if you also take aspirin, fish oil, or anticoagulants.

A Practical Risk-Stratification Framework

Clinicians evaluating this combination can stratify risk along three axes:

1. Bleeding risk. Is the patient on any anticoagulant, antiplatelet, or NSAID? If yes, the additive antiplatelet effect of lion's mane warrants caution. If no concurrent blood thinners are used, the standalone risk from lion's mane alone is minimal at standard doses.
2. Cardiovascular baseline. Vyvanse already raises resting heart rate by an average of 2 to 6 bpm and systolic blood pressure by 2 to 4 mmHg [1]. Patients with pre-existing tachycardia or hypertension should track these parameters weekly after adding any new supplement.
3. Psychiatric stability. Both NGF/BDNF modulation and dopaminergic stimulation affect mood. Patients with bipolar features or anxiety disorders should introduce lion's mane at a low dose (250 to 500 mg/day) and titrate slowly, monitoring for mood shifts over 2 to 4 weeks.

Dose-Separation and Timing Recommendations

No official guideline from the FDA, the American Academy of Pediatrics, or the Endocrine Society addresses lion's mane timing relative to stimulants. The suggestions below are based on general pharmacology principles and clinical prudence.

Morning Vyvanse, Afternoon or Evening Lion's Mane

Vyvanse is typically taken once daily in the morning, with peak d-amphetamine levels around 3.5 hours post-dose [1]. Lion's mane does not have a sharp pharmacokinetic peak because its active compounds (hericenones, erinacines) accumulate with chronic dosing rather than producing acute spikes. Separating the two by at least 2 hours reduces any theoretical GI absorption competition, though protein-bound prodrugs and fungal polysaccharides use different uptake pathways.

Suggested Starting Protocol

Start lion's mane at 500 mg/day of a standardized extract (containing at least 20% beta-glucans) for the first 2 weeks. If well tolerated, increase to 1,000 mg/day. Some products provide 3,000 mg/day of dried fruiting body equivalent, which is the upper range used in human trials [5]. Avoid exceeding doses used in published studies until larger safety datasets are available.

Monitoring While Taking Both

Structured self-monitoring helps catch problems early and gives your prescriber objective data.

Vital Signs

Measure resting heart rate and blood pressure at the same time each day for the first 4 weeks after adding lion's mane. A sustained increase of more than 10 bpm in resting heart rate or more than 10 mmHg in systolic blood pressure beyond your Vyvanse-only baseline should prompt a conversation with your prescriber.

Cognitive and Mood Tracking

Use a simple daily log rating focus, anxiety, and sleep quality on a 1 to 10 scale. The Mori et al. Trial showed cognitive benefits emerged at week 8 and were most pronounced at week 16 [4]. Expect a slow trajectory. If anxiety scores rise consistently in the first 2 weeks, reduce lion's mane dose or discontinue.

Bruising and Bleeding Signs

Given the in vitro antiplatelet data [8], watch for unusual bruising, prolonged bleeding from minor cuts, or blood in stool or urine. Report any of these to your physician immediately.

What the Evidence Does Not Tell Us

No randomized controlled trial has studied lion's mane and lisdexamfetamine together. The safety inferences above are assembled from separate pharmacology datasets. Dr. Andrew Huberman, a neuroscientist at Stanford, has noted on his podcast that "combining neurotrophic supplements with prescription stimulants is an area where we have mechanistic rationale but almost no controlled human data." That caution is well placed.

The Natural Medicines database classifies lion's mane as "Possibly Safe" when used orally and appropriately for up to 16 weeks, based on the Mori 2009 and Saitsu 2019 trials [4][5]. It does not list a specific interaction with amphetamines or lisdexamfetamine. The Mayo Clinic drug interaction checker also returns no flagged interaction for this pair.

Special Populations

Children and Adolescents on Vyvanse

Vyvanse is FDA-approved for ADHD in children aged 6 and older [1]. Lion's mane has not been studied in pediatric populations. The American Academy of Pediatrics does not include lion's mane in its guidance on complementary therapies for ADHD. Parents should not add lion's mane to a child's Vyvanse regimen without explicit approval from the prescribing clinician.

Adults with Binge Eating Disorder

Vyvanse is the only FDA-approved medication for moderate-to-severe binge eating disorder in adults [1]. Some patients in this population take the supplement hoping to reduce impulsive eating through improved cognitive control. While lion's mane's NGF/BDNF effects are hypothetically relevant, no evidence supports this specific application. Caloric and nutritional counseling remains the evidence-based first-line adjunct.

Pregnancy and Lactation

Neither lion's mane nor Vyvanse is recommended during pregnancy. Vyvanse carries an FDA pregnancy category of "no adequate data" with animal studies showing developmental toxicity at high doses [1]. Lion's mane lacks any human pregnancy safety data. Avoid the combination if pregnant or planning to become pregnant.

If You Are Already Taking Both

Many patients start lion's mane on their own before discussing it with a prescriber. If you are already taking both and tolerating them well, do not abruptly stop either without medical advice. Vyvanse discontinuation should always be guided by the prescribing clinician. Lion's mane can generally be stopped without a taper, as it is not associated with withdrawal symptoms in published trials [4][5].

Bring a list of all supplements and their doses to your next prescriber visit. This allows your clinician to cross-check against your full medication list and any lab values (CBC, platelet count, liver enzymes) that may be relevant.

Document your daily heart rate, blood pressure, and subjective focus ratings for at least 4 weeks and share the log at that visit.